Hematologic Malignancies Program
About Hematologic Malignancies Program
Since lymphoma is a cancer of the immune system, a major scientific goal of the Hematologic Malignancies Program is to use knowledge gained from immunology to understand and treat lymphoid malignancies. This goal is being accomplished by gaining better understanding of the biology underlying lymphoid and myeloid neoplasms and applying this knowledge to improve the diagnosis and treatment of these disorders.
- Discover the Genetic and Cellular Origins of Lymphomas and Leukemias
- Develop Novel Methods of Diagnosis and Biomarker Monitoring of these Diseases
- Develop New Therapies
Hematologic Malignancies Clinical Trials
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and OsteosarcomaStanford is currently accepting patients for this trial.
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsStanford is currently accepting patients for this trial.
Stanford is currently accepting patients for this trial.
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell MalignanciesStanford is currently accepting patients for this trial.